The federal safety study of mifepristone that could reshape how the abortion pill is dispensed in the United States has not been completed, and the agency's own public status page describes it as still moving through data analysis and peer review.
Two separate developments have moved while that study sits unfinished. The agency approved a third supplier in 2025, joining the brand product and the generic available since 2019. And in late August, the Senate health committee's Republican majority released a report accusing all three sponsors of failing to police the prescribers who sell their product. The rules governing how any of them reach a patient have not changed.
